Relay Therapeutics to Participate in Fireside Chat at Bank of America 2021 Health Care ConferenceGlobeNewsWire • 05/05/21
Relay Therapeutics Expands Clinical Leadership Team with Addition of Tara O'Meara and Charles FertéGlobeNewsWire • 05/03/21
Relay Therapeutics Extends Leadership in Integrating Computational and Experimental Approaches to Create Precision Medicines by Acquiring ZebiAIGlobeNewsWire • 04/16/21
Relay Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational HighlightsGlobeNewsWire • 03/25/21
Relay Therapeutics to Present Preclinical Data on RLY-4008 at AACR Annual MeetingGlobeNewsWire • 03/10/21
Relay Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2021 Oncology DayGlobeNewsWire • 02/04/21
Relay Therapeutics to Present at 39th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/06/21
Relay Therapeutics Announces a Worldwide License and Collaboration Agreement with Genentech for RLY-1971GlobeNewsWire • 12/14/20
Relay Therapeutics: Heavily Backed Biotech Brains Trust Looks A Long-Term BuySeeking Alpha • 09/07/20
Relay Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Trial of RLY-4008, a Highly Selective FGFR2 InhibitorGlobeNewsWire • 09/03/20
Relay Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 07/20/20
Relay Therapeutics's stock sprints out of the gate, after upsized IPO priced above recently raised expectationsMarket Watch • 07/16/20
Relay Therapeutics IPO Raises $400 Million, Exceeding ExpectationsInvestors Business Daily • 07/16/20